The week in industry: GBP £45 million awarded to tackle life threatening diseases
This week: Ned Sharpless to become acting chief of the FDA, the SMC does not approve of KYMIRAH® for patients with lymphoma on the NHS and collaboration announced to advance treatments for dermatology conditions.
Please sign in or register for FREE
Sign in to RxNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Future Medicinal Chemistry FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RxNet account also gives you access to communities on regenerative medicine, real-world evidence and 3D printing in medicine. Find out more>>